Deep dives into cell therapy partnerships, Japan market entry, and strategic execution.
December 10, 2025
How interest rates and geopolitical shifts are affecting asset pricing in cross-border deals.
Read Article →January 13, 2025
The semiconductor industry learned that vertical integration of design and manufacturing creates sustainable competitive advantage. Cell therapy is learning the same lesson.
Read Article →January 20, 2025
In-house manufacturing, CDMO partnerships, or strategic manufacturing alliances—the right choice depends on your stage, volume trajectory, and differentiation strategy.
Read Article →January 27, 2025
Platform acquisitions and product acquisitions require fundamentally different valuation approaches. Getting this distinction wrong leads to either overpaying for products or undervaluing platforms.
Read Article →January 6, 2025
A comprehensive guide to cell therapy partnerships, covering manufacturing integration, deal structures, technology evolution, and strategic entry frameworks.
Read Article →January 6, 2025
Five characteristics consistently appear in cell therapy partnerships that succeed: manufacturing mastery, platform value recognition, cost trajectory alignment, stage-appropriate structures, and geographic complementarity.
Read Article →February 3, 2025
Manufacturing time affects T-cell phenotype, patient access, and commercial economics. Speed-to-patient is emerging as the critical differentiator in cell therapy competition.
Read Article →February 10, 2025
Generation number is less predictive of clinical success than specific design choices. This guide provides a framework for evaluating next-generation claims.
Read Article →February 17, 2025
Solid tumor CAR-T represents the highest-risk, highest-potential opportunity in cell therapy. Regional delivery and tumor microenvironment engineering are showing early signals of activity.
Read Article →February 24, 2025
Autologous CAR-T dominates today, but allogeneic, CAR-NK, and in vivo platforms offer portfolio diversification for strategic acquirers evaluating cell therapy entry.
Read Article →March 3, 2025
From Legend-Janssen profit-sharing to AstraZeneca-Gracell platform acquisition, the deal structures that succeed share common elements of risk allocation and incentive alignment.
Read Article →March 10, 2025
Cell therapy is not a closed market. New targets, manufacturing innovations, geographic opportunities, and modality evolution continue to create entry points for thoughtful latecomers.
Read Article →January 15, 2024
Why entering Japan requires more than just translation. Understanding the regulatory and cultural nuances.
Read Article →